Entrada Therapeutics (TRDA) IPO Opens 33% Higher

Today’s IPO for Entrada Therapeutics (NASDAQ: TRDA) opened for trading at $26.50 after pricing 9,075,000 shares of common stock, at a price to the public of $20.00 per share.

Goldman Sachs & Co. LLC, Cowen and Company, LLC and Evercore Group L.L.C. are acting as joint book-running managers for the offering.

Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), to engage intracellular targets that have long been considered inaccessible and undruggable.

You May Also Be Interested In

• Goldman, BofA vie to manage Anthropic employee wealth post-IPO - report
• Anthropic Nears Tapping Morgan Stanley, Goldman For IPO - FT
• Yarrow Bioscience prices $150M public offering at $26 per share